 |
|
All Releases
 |
OXiGENE Reports First Quarter 2013 Financial Results
May 6, 2013
|
18.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 6, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the quarter ended March 31, 2013.
Financial Results
For the three months ended March 31, 2013, the Company reported a net l...
|
|
OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial
Apr 24, 2013
|
14.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that enrollment has been completed in a randomized Phase 2 clinical trial testing the combination of ZYBRESTAT® (fosbretabulin; CA-4P) plus bevacizumab ...
|
|
OXiGENE Announces First Quarter 2013 Earnings Conference Call and Webcast
Apr 24, 2013
|
11.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report first quarter 2013 results on Monday, May 6, 2013. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT).
...
|
|
OXiGENE Announces $5 Million Private Placement
Apr 11, 2013
|
14.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 11, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it has entered into definitive agreements with institutional accredited investors in a private placement of $5.0 million of zero coupon convertible pref...
|
|
OXiGENE Announces Issuance of Patent for Benzosuberenes, a Novel Anticancer Class of Agents
Mar 20, 2013
|
14.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today that the US Patent and Trademark Office issued U.S. Patent No. 8,397,859, covering certain benzosuberene-based compounds, including the analogues refer...
|
|
OXiGENE Reports Full Year 2012 Financial Results
Mar 12, 2013
|
19.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 12, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended December 31, 2012.
Financial Results
For the year ended December 31, 2012, the Company reported a net los...
|
|
OXiGENE Announces Year-End 2012 Earnings Conference Call and Webcast
Mar 4, 2013
|
12.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report year-end 2012 results on Tuesday, March 12, 2013. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT).
...
|
|
OXiGENE Announces ZYBRESTAT(R) Plus Avastin(R) Continues to be Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Ovarian Cancer Trial
Feb 6, 2013
|
15.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb. 6, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today that the randomized Phase 2 study evaluating the combination of ZYBRESTAT® (fosbretabulin tromethamine or CA4P) and Avastin® (bevacizumab) to t...
|
|
OXiGENE Announces Presentation at BIO CEO Conference on February 12th
Feb 4, 2013
|
11.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb. 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that Peter Langecker, M.D., PhD., President and Chief Executive Officer, will provide a corporate overview at the 15th annual BIO-CEO & Investor conference on ...
|
|
OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors
Jan 23, 2013
|
13.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David (Dai) Chaplin, Ph.D., has been appointed to its board of directors. Dr. Chaplin formerly served as chief scientific officer and head of research an...
|
|
OXiGENE Regains Nasdaq Closing Bid Price Compliance
Jan 16, 2013
|
11.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that on January 14, 2013, Nasdaq notified the Company that it regained compliance with the minimum $1.00 per share closing bid price requirement for con...
|
|
OXiGENE Announces Presentation of Encouraging OXi4503 Preclinical and Clinical Data in Acute Myelogenous Leukemia at American Society of Hematology Meeting
Dec 10, 2012
|
16.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today that investigators at the University of Florida presented encouraging clinical data using OXiGENE's vascular disrupting agent (VDA), OXi4503, in patient...
|
|
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
Nov 21, 2012
|
15.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that its product candidate OXi4503 has been granted orphan designation by the US Food and Drug Administration for the treatment of acute myelogenous leukemia ...
|
|
OXiGENE Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease, Polypoidal Choroidal Vasculopathy (PCV), Presented at the American Academy of Ophthalmology 2012 Annual Meeting
Nov 12, 2012
|
15.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the presentation today of data from a Phase 2 trial of ZYBRESTAT (fosbretabulin) in patients with polypoidal choroidal vasculopathy (PCV), which has features ...
|
|
OXiGENE Reports Third Quarter 2012 Financial Results
Nov 8, 2012
|
23.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 8, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the quarter and nine months ending September 30, 2012.
For the three months ended September 30, 2012, the Company reported a net l...
|
|
OXiGENE Announces Presentation at BIO-Europe Conference on November 14th
Nov 5, 2012
|
12.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that Peter Langecker, M.D., PhD., President and Chief Executive Officer, will provide a corporate overview at the 18th annual BIO-Europe international partneri...
|
|
OXiGENE Announces Third Quarter 2012 Earnings Conference Call and Webcast
Nov 1, 2012
|
10.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 1, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report third quarter 2012 results on Thursday, November 8, 2012. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm EDT (1:30 p.m. PDT...
|
|
OXiGENE Announces Agreement With FDA on Special Protocol Assessment for a Phase 3 Trial of ZYBRESTAT(R) in Anaplastic Thyroid Cancer
Sep 17, 2012
|
14.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it has come to agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for its Phase 3 clinical trial (FACT 2)...
|
|
OXiGENE to Present Data Showing Importance of Local Site Pathology Confirmation in Phase 2/3 Clinical Trial of Zybrestat(R) in Anaplastic Thyroid Cancer
Sep 7, 2012
|
14.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Sept. 7, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the presentation of data from the Phase 2/3 trial (FACT) of ZYBRESTAT in patients with anaplastic thyroid cancer (ATC), showing that patients enrolled in the ...
|
|
OXiGENE Expands ZYBRESTAT Named Patient Program With Azanta A/S
Aug 22, 2012
|
14.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the company has amended the Limited Distribution Agreement, established in December 2011, with Azanta Danmark A/S to include additional territories. The ...
|
|
|
= add release to Briefcase |
|
 |
|
3:23 PM ET - 05/24/13 |
|
$3.27
( 0.04)
|
Volume | 10,400 |
Day High | 3.31 |
Day Low | 3.25 |
52-week High | 11.76 |
52-week Low | 3.10 |
» more |
|
|
|
|
 |
|
 |
|
Shareholder Briefcase
Mobile Investor
Download Library
RSS News Feeds
Snapshot
| |
|
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
